Pfizer, BioNTech deny talks with Thai Thonburi Healthcare on vaccines



(Updates with denial from Pfizer)

By Chayut Setboonsarng

BANGKOK, July 15 (Reuters) - Pfizer PFE.N and Germany's BioNTech 22UAy.DE denied on Thursday that they were in talks with Thailand's Thonburi Healthcare Group Pcl THG.BK for a deal to import 20 million doses of the coronavirus vaccine to the Southeast Asian country.

The chief of Thonburi Healthcare Group had said earlier in the day that it would sign a private order for 20 million doses of the Pfizer-BioNTech vaccine, news of which saw the hospitals operator's share price leap over 13%.

"We are not in negotiations with the company," BioNTech said in an e-mail responding to a Reuters query about the deal. It also denied it was in negotiations with any Thai entity.

Company chairman Boon Vanasin had told Reuters a deal would be signed on Thursday with BioNTech, the German firm that jointly developed the mRNA vaccine with Pfizer.

Asked about the companies' denial, Boon later insisted a vaccine deal was still in the works, saying: "We are not doing it directly." He declined to elaborate.

A Pfizer spokesman said the company was only in discussions with Thailand's health ministry and disease control department.

"Neither Pfizer Inc nor any of its affiliates globally, have authorized anyone to import, market, distribute the Pfizer-BioNTech COVID-19 vaccine," he said.

It was not immediately possible to reconcile the conflicting statements by Boon and the two companies.

Thailand is in the early stages of its mass COVID-19 vaccinations programme and is struggling to suppress its most severe wave of infections.

It has relied heavily on the AstraZeneca AZN.L and Sinovac SVA.O vaccines but is seeing increased demand for mRNA type vaccines, after concern about efficacy. The majority of the mRNA vaccines ordered will not arrive until the fourth quarter this year.

Boon had said a licensed importer in Thailand would make an announcement on the deal. "I want it to conclude this week or next," he said.

Boon, who has been a vocal critic of the government's vaccine policy, said he had asked for a delivery of 5 million doses this month under the negotiations.

Shares of the hospital group rose as much 13.45% by 0540 GMT, with the benchmark index .SETI up 0.62% on earlier reports of the plans.

The state drugmaker, the Government Pharmaceutical Organization, said on Wednesday it had filed a defamation suit against Boon over his criticism of its role in the procurement of Moderna vaccines MRNA.O .
Reporting by Chayut Setboonsarng, additional reporting by Kay Johnson, Ludwig Burger in Frankfurt; Editing by Martin Petty, Philippa Fletcher and Kim Coghill

Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.

Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.

Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.

Gumagamit kami ng cookies para mabigyan ka ng mahusay na karanasan sa aming website. Magbasa pa o palitan ang iyong cookie settings.

Babala sa Risk: Ang iyong kapital ay maaaring malugi. Ang mga produktong naka-leverage ay maaaring hindi para sa lahat. Tingnan ang aming Risk Disclosure.